Discover why psoriasis treatments may lose effectiveness and explore alternatives. Learn about the potential of biologics, systemic therapies, and more to manage symptoms.

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Takeda’s zasocitinib has shown strong rates of skin clearance, as well as other benefits, in new study results regarding ...

Patients with psoriasis are at increased risk for cataracts, uveitis, dry eye disease, glaucoma, retinal vein occlusion (RVO) ...

Metabolic bariatric surgery (MBS) is associated with improved outcomes in patients with psoriasis, according to a review ...

Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and ...

Psoriasis can increase skin infection risk due to effects from the condition and its treatments. Learn about potential infections, symptoms, and preventive measures.

For the 7.5 million Americans diagnosed with psoriasis, it can be disheartening to hear that there's no cure. But there are several treatments that can help keep this autoimmune disease under control.

CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased ...

NB-UVB phototherapy may restore adalimumab efficacy in chronic plaque psoriasis after treatment failure. Learn more about ...

Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time.